Jacqualyn A. Fouse
CIK: 0001405288
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2.8K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectStock options (right to buy)
15K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectRestricted stock units
2.9K shares- - Jun 17, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Award(A)Direct454 shares- - Jun 8, 2026INCY
INCYTE CORP
Award(A)Direct1.6K shares- - Jun 20, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Award(A)Direct203 shares- - Jun 20, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2.1K shares- - Jun 18, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectStock options (right to buy)
15.8K shares- - Jun 18, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectRestricted stock units
2.8K shares- - Jun 10, 2025INCY
INCYTE CORP
Award(A)Direct2.5K shares- - Apr 10, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct7.5K shares at avg. $25.90$194K - Apr 8, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct15.9K shares- - Mar 10, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Award(A)Direct894 shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 18, 2026 |  AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 2,816 | - | $0 | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Stock options (right to buy) | 14,950 | - | - | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Restricted stock units | 2,927 | - | - | Direct |
| Jun 17, 2026 |  MDGL MADRIGAL PHARMACEUTICALS, INC. | Award(A) | 454 | - | $0 | Direct |
| Jun 8, 2026 |  INCY INCYTE CORP | Award(A) | 1,642 | - | $0 | Direct |
| Jun 20, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Award(A) | 203 | - | - | Direct |
| Jun 20, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 2,120 | - | - | Direct |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Stock options (right to buy) | 15,768 | - | - | Direct |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Restricted stock units | 2,816 | - | - | Direct |
| Jun 10, 2025 | INCY INCYTE CORP | Award(A) | 2,518 | - | - | Direct |
| Apr 10, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 7,497 | $25.90 | $194,172 | Direct |
| Apr 8, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 15,933 | - | - | Direct |
| Mar 10, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Award(A) | 894 | - | - | Direct |
1-13 of 13 transactions
About FOUSE JACQUALYN A
FOUSE JACQUALYN A (SEC CIK 0001405288) files insider reports with the SEC as Director of AGIOS PHARMACEUTICALS, INC. (AGIO), Director of MADRIGAL PHARMACEUTICALS, INC. (MDGL) and Director of INCYTE CORP (INCY).
Signal8 holds 9 ownership filings by FOUSE JACQUALYN A (1 Form 3, 8 Form 4), filed between Mar 12, 2025 and Jun 23, 2026. Those filings report 13 transactions, from Mar 10, 2025 to Jun 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on FOUSE JACQUALYN A's filings is in WILMINGTON, DE.
Recent filings by FOUSE JACQUALYN A
- Jun 18, 2026: Option exercise of AGIO shares (Form 4, code M).
- Jun 18, 2026: Grants or awards of AGIO derivative securities (2 lines, Form 4, code A).
- Jun 17, 2026: Grant or award of MDGL shares (Form 4, code A).
- Jun 8, 2026: Grant or award of INCY shares (Form 4, code A).
- Jun 20, 2025: Grant or award of MDGL shares (Form 4, code A).
Other insiders filing for AGIOS PHARMACEUTICALS, INC. (AGIO)
- Gheuens Sarah, Chief Medical Officer
- Backstrom Jay T., Director
- Ballal Rahul D., Director
- CAPELLO JEFFREY D, Director
- Foster-Cheek Kaye I, Director
- Ho Maykin, Director